Delaware Chapter of the American College of CardiologyOur purpose is to contribute to the prevention of cardiovascular diseases, to ensure optimal quality of care for individuals with such diseases, and to foster the highest professional ethical standards. Please let us know what information you want to see here. Feel free to contact us with your ideas, needs and comments. |
ACC Live Courses For a listing of all ACC Live Courses please visit: https://www.acc.org/education-and-meetings/meetings |
Latest in Cardiology from ACC.org
- Real-time AI to Influence Clinical Decisions and Practice Towards Evidence-based Care: RAPIDxAI TrialIn this interview, Drs. Allen Taylor and Derek Chew discuss the findings of the RAPIDxAI trial: re-engineering the clinical approach to suspected cardiac chest pain assessment in the emergency department by expediting evidence to practice using AI.
- ECLIPSE: Orbital Atherectomy vs. Conventional Balloon Angioplasty Prior to DES ImplantationThe routine use of orbital atherectomy did not improve minimal stent area (MSA) or reduce target vessel failure (TVF) at one year compared with conventional balloon angioplasty prior to implantation of a drug-eluting stent (DES) in severely calcified coronary lesions...
- Systolic BP Polygenic Risk Score With Chlorthalidone ResponseWhat is the ability of a systolic blood pressure (SBP) polygenic risk score (PRS) to predict antihypertensive treatment (AHT) response and apparent treatment-resistant hypertension (aTRH)?
- CONFIRM2: AI-Guided QCT May Help Reduce CV Events in Patients With Suspected CADAI-guided Quantitative Coronary Computed Tomography Angiography (AI-QCT) may help guide tailoring of anti-atherosclerotic therapies or coronary interventional procedures to reduce cardiovascular events in patients with suspected coronary artery disease (CAD), based on findings from the CONFIRM-2 trial presented at TCT 2024.
- Percutaneous Coronary Intervention With a Bioadaptor Compared to a Contemporary Drug-Eluting StentThe goal of the INFINITY-SWEDEHEART trial was to compare the efficacy of the DynamX bioadaptor, a novel coronary implantable device, to a contemporary drug-eluting stent (DES) in the treatment of coronary artery disease requiring percutaneous coronary intervention (PCI).